Cutaneous sclerosis

Common Name(s)

Cutaneous sclerosis

Cutaneous sclerosis is a rare disease in which the skin develops thicker layers and or scars. While this condition primarily affects the skin, these symptoms can also be found in other tissues and joints. Individuals with cutaneous sclerosis have an overproduction of collagen (a protein needed for connective tissue) by the skin cells during the healing process. Although the cause is not always known, it is seen in 10-20% of persons with graft-versus-host disease (please also visit: graft versus host disease.) which occurs after a transplant of cells, tissues, or organs.

Symptoms of cutaneous sclerosis include visible changes to the skin where is looks thick, feels tight and does not move easily. The diagnosis is confirmed by taking a skin sample and studying it under a microscope. Cutaneous sclerosis is often treated by oral steroids and immunosuppressive treatments to decrease the activity of the immune system (your body’s response to infection). Other more specialized treatments are sometimes needed if these fail. If you or a family member has been diagnosed with cutaneous sclerosis, talk with your doctor or specialist about the most current treatment options. There are support groups for more general scleroderma diagnosis, which provide additional resources.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Cutaneous sclerosis" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Cutaneous sclerosis" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Cutaneous sclerosis" returned 74 free, full-text research articles on human participants. First 3 results:

Tuberous Sclerosis with Severe Cutaneous Manifestation and Multiples Facial Angiofibromas.
 

Author(s): Natália Galvão Garcia, Marina Lara de Carli, Denise Tostes Oliveira, Cléverson Teixeira Soares, Noé Vital Ribeiro Júnior, Felipe Fornias Sperandio, João Adolfo Costa Hanemann

Journal: Head Neck Pathol. 2016 Dec;10(4):542-546.

 

Tuberous sclerosis is an extremely variable disease that can affect virtually any organ in the body. The most common findings are cutaneous manifestations, that are critical features in helping to establish diagnosis. We present a case of young man with diagnosis of tuberous sclerosis ...

Last Updated: 3 May 2016

Go To URL
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.
 

Author(s): Rucsandra Dobrota, Britta Maurer, Nicole Graf, Suzana Jordan, Carina Mihai, Otylia Kowal-Bielecka, Yannick Allanore, Oliver Distler,

Journal: Ann. Rheum. Dis.. 2016 Oct;75(10):1743-8.

 

Improvement of skin fibrosis is part of the natural course of diffuse cutaneous systemic sclerosis (dcSSc). Recognising those patients most likely to improve could help tailoring clinical management and cohort enrichment for clinical trials. In this study, we aimed to identify predictors ...

Last Updated: 10 Sep 2016

Go To URL
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.
 

Author(s): Nicola S Orefice, Mireille Alhouayek, Antonio Carotenuto, Silvana Montella, Franscesco Barbato, Albert Comelli, Antonio Calignano, Giulio G Muccioli, Giuseppe Orefice

Journal: Neurotherapeutics. 2016 Apr;13(2):428-38.

 

Palmitoylethanolamide (PEA) is an endogenous lipid mediator known to reduce pain and inflammation. However, only limited clinical studies have evaluated the effects of PEA in neuroinflammatory and neurodegenerative diseases. Multiple sclerosis (MS) is a chronic autoimmune and inflammatory ...

Last Updated: 7 Apr 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Cutaneous sclerosis" returned 2 free, full-text review articles on human participants. First 3 results:

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
 

Author(s): Dinesh Khanna, Veronica J Berrocal, Edward H Giannini, James R Seibold, Peter A Merkel, Maureen D Mayes, Murray Baron, Philip J Clements, Virginia Steen, Shervin Assassi, Elena Schiopu, Kristine Phillips, Robert W Simms, Yannick Allanore, Christopher P Denton, Oliver Distler, Sindhu R Johnson, Marco Matucci-Cerinic, Janet E Pope, Susanna M Proudman, Jeffrey Siegel, Weng Kee Wong, Athol U Wells, Daniel E Furst

Journal: Arthritis Rheumatol. 2016 Feb;68(2):299-311.

 

Early diffuse cutaneous systemic sclerosis (dcSSc) is characterized by rapid changes in the skin and internal organs. The objective of this study was to develop a composite response index in dcSSc (CRISS) for use in randomized controlled trials (RCTs).

Last Updated: 26 Jan 2016

Go To URL
[Efficacy of anti-thymocyte globulin and cyclosporin A combined therapy in aplastic anemia complicated with limited cutaneous systemic sclerosis].
 

Author(s): Eiichi Suematsu, Tomoya Miyamura, Kensaku Idutsu, Rumi Minami, Masahiro Yamamoto

Journal: Nihon Rinsho Meneki Gakkai Kaishi. 2005 Apr;28(2):99-103.

 

We reported here on a case of limited cutaneous systemic sclerosis (lcSSc) with aplastic anemia treated by anti-thymocyte globulin and cyclosporin A. The use of this therapy resulted not only in marrow recovery but also in resolution of the skin sclerosis. A 68 year-old woman was ...

Last Updated: 2 May 2005

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
 

Status: Recruiting

Condition Summary: Scleroderma, Diffuse; Diffuse Cutaneous Systemic Sclerosis

 

Last Updated: 13 Jun 2016

Go to URL
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
 

Status: Recruiting

Condition Summary: Scleroderma, Diffuse; Scleroderma, Systemic; Scleroderma, Limited; Sclerosis, Progressive Systemic; Skin Diseases; Connective Tissue Diseases; Pathologic Processes; Autoimmune Diseases

 

Last Updated: 22 Feb 2017

Go to URL
Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis
 

Status: Not yet recruiting

Condition Summary: Scleroderma, Systemic

 

Last Updated: 2 May 2017

Go to URL